Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β-1b therapy

Joon H. Uhm, Nora P. Dooley, Olaf Stuve, Gordon S. Francis, Pierre Duquette, Jack P. Antel, Voon Wee Yong

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Previous reports by our group and by others have shown that in vitro treatment of T cells derived from healthy, normal subjects with interferon β-1b (IFN-β1b) reduces metalloproteinase (metalloproteinase type 9 [MMP-9]) activity with a consequent reduction in lymphocyte migration. In this study, we used a Boyden chamber assay to assess the migratory capacity of T cells derived from multiple sclerosis patients who either did or did not receive IFN-β1b. Lymphocytes derived from patients treated for less than 2 years with IFN-β migrated at a low rate that was indistinguishable from that of cells isolated from healthy donors. However, longer term treatment with IFN (>3.5 years) was associated with a reversion of the migration to a high level that did not differ statistically from that of cells isolated from untreated multiple sclerosis patients. For both high-migratory groups, migration could be reduced to control levels after the exogenous addition of TIMP-1, a relatively specific inhibitor of the MMP-9, implicating this protease in the process of T-cell migration. Our findings suggest that one of the mechanisms by which IFN-β exerts its action is by reducing MMP-9 activity and thus the entry of inflammatory cells into the nervous system and, as such, MMPs may constitute potential therapeutic targets in inflammatory diseases such as multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalAnnals of Neurology
Volume46
Issue number3
DOIs
StatePublished - 1999

Fingerprint

Metalloproteases
Interferons
Multiple Sclerosis
Lymphocytes
T-Lymphocytes
Therapeutics
Tissue Inhibitor of Metalloproteinase-1
Matrix Metalloproteinases
Nervous System
Cell Movement
Healthy Volunteers
Peptide Hydrolases
Tissue Donors

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Migratory behavior of lymphocytes isolated from multiple sclerosis patients : Effects of interferon β-1b therapy. / Uhm, Joon H.; Dooley, Nora P.; Stuve, Olaf; Francis, Gordon S.; Duquette, Pierre; Antel, Jack P.; Yong, Voon Wee.

In: Annals of Neurology, Vol. 46, No. 3, 1999, p. 319-324.

Research output: Contribution to journalArticle

Uhm, Joon H. ; Dooley, Nora P. ; Stuve, Olaf ; Francis, Gordon S. ; Duquette, Pierre ; Antel, Jack P. ; Yong, Voon Wee. / Migratory behavior of lymphocytes isolated from multiple sclerosis patients : Effects of interferon β-1b therapy. In: Annals of Neurology. 1999 ; Vol. 46, No. 3. pp. 319-324.
@article{97e377315f4d4624996bcf18d1fd6dd2,
title = "Migratory behavior of lymphocytes isolated from multiple sclerosis patients: Effects of interferon β-1b therapy",
abstract = "Previous reports by our group and by others have shown that in vitro treatment of T cells derived from healthy, normal subjects with interferon β-1b (IFN-β1b) reduces metalloproteinase (metalloproteinase type 9 [MMP-9]) activity with a consequent reduction in lymphocyte migration. In this study, we used a Boyden chamber assay to assess the migratory capacity of T cells derived from multiple sclerosis patients who either did or did not receive IFN-β1b. Lymphocytes derived from patients treated for less than 2 years with IFN-β migrated at a low rate that was indistinguishable from that of cells isolated from healthy donors. However, longer term treatment with IFN (>3.5 years) was associated with a reversion of the migration to a high level that did not differ statistically from that of cells isolated from untreated multiple sclerosis patients. For both high-migratory groups, migration could be reduced to control levels after the exogenous addition of TIMP-1, a relatively specific inhibitor of the MMP-9, implicating this protease in the process of T-cell migration. Our findings suggest that one of the mechanisms by which IFN-β exerts its action is by reducing MMP-9 activity and thus the entry of inflammatory cells into the nervous system and, as such, MMPs may constitute potential therapeutic targets in inflammatory diseases such as multiple sclerosis.",
author = "Uhm, {Joon H.} and Dooley, {Nora P.} and Olaf Stuve and Francis, {Gordon S.} and Pierre Duquette and Antel, {Jack P.} and Yong, {Voon Wee}",
year = "1999",
doi = "10.1002/1531-8249(199909)46:3<319::AID-ANA7>3.0.CO;2-N",
language = "English (US)",
volume = "46",
pages = "319--324",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Migratory behavior of lymphocytes isolated from multiple sclerosis patients

T2 - Effects of interferon β-1b therapy

AU - Uhm, Joon H.

AU - Dooley, Nora P.

AU - Stuve, Olaf

AU - Francis, Gordon S.

AU - Duquette, Pierre

AU - Antel, Jack P.

AU - Yong, Voon Wee

PY - 1999

Y1 - 1999

N2 - Previous reports by our group and by others have shown that in vitro treatment of T cells derived from healthy, normal subjects with interferon β-1b (IFN-β1b) reduces metalloproteinase (metalloproteinase type 9 [MMP-9]) activity with a consequent reduction in lymphocyte migration. In this study, we used a Boyden chamber assay to assess the migratory capacity of T cells derived from multiple sclerosis patients who either did or did not receive IFN-β1b. Lymphocytes derived from patients treated for less than 2 years with IFN-β migrated at a low rate that was indistinguishable from that of cells isolated from healthy donors. However, longer term treatment with IFN (>3.5 years) was associated with a reversion of the migration to a high level that did not differ statistically from that of cells isolated from untreated multiple sclerosis patients. For both high-migratory groups, migration could be reduced to control levels after the exogenous addition of TIMP-1, a relatively specific inhibitor of the MMP-9, implicating this protease in the process of T-cell migration. Our findings suggest that one of the mechanisms by which IFN-β exerts its action is by reducing MMP-9 activity and thus the entry of inflammatory cells into the nervous system and, as such, MMPs may constitute potential therapeutic targets in inflammatory diseases such as multiple sclerosis.

AB - Previous reports by our group and by others have shown that in vitro treatment of T cells derived from healthy, normal subjects with interferon β-1b (IFN-β1b) reduces metalloproteinase (metalloproteinase type 9 [MMP-9]) activity with a consequent reduction in lymphocyte migration. In this study, we used a Boyden chamber assay to assess the migratory capacity of T cells derived from multiple sclerosis patients who either did or did not receive IFN-β1b. Lymphocytes derived from patients treated for less than 2 years with IFN-β migrated at a low rate that was indistinguishable from that of cells isolated from healthy donors. However, longer term treatment with IFN (>3.5 years) was associated with a reversion of the migration to a high level that did not differ statistically from that of cells isolated from untreated multiple sclerosis patients. For both high-migratory groups, migration could be reduced to control levels after the exogenous addition of TIMP-1, a relatively specific inhibitor of the MMP-9, implicating this protease in the process of T-cell migration. Our findings suggest that one of the mechanisms by which IFN-β exerts its action is by reducing MMP-9 activity and thus the entry of inflammatory cells into the nervous system and, as such, MMPs may constitute potential therapeutic targets in inflammatory diseases such as multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0032880358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032880358&partnerID=8YFLogxK

U2 - 10.1002/1531-8249(199909)46:3<319::AID-ANA7>3.0.CO;2-N

DO - 10.1002/1531-8249(199909)46:3<319::AID-ANA7>3.0.CO;2-N

M3 - Article

C2 - 10482262

AN - SCOPUS:0032880358

VL - 46

SP - 319

EP - 324

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 3

ER -